2
Introduction
In the United States each year, more than 14,000 new cases of glioblastoma (GBM), the World Health Organization grade IV brain cancer, will be diagnosed (1). Despite the current standard of maximal safe surgical resection followed by radiotherapy and chemotherapy with the alkylating agent temozolomide, patients have an overall median survival of less than two years (2) . Thus, there is an urgent need to find new prognostic biomarkers to inform clinical management and therapies to improve outcome.
Ion channels, transmembrane proteins regulating ion flux across the plasma membrane, have been reported to influence progression of GBM and other cancers (3) (4) (5) (6) (7) (8) . Kv.11.1, encoded by the human Ether-à-go-go Related Gene (hERG, or KCNH2), is well characterized for its role in cardiac repolarization (9, 10) . It is the primary target for acquired or drug-induced long QT syndrome, leading in some cases to sudden cardiac death. However, many hERG blockers are in clinical use and known to be generally safe (11) . hERG was shown to be overexpressed in leukemia, gastric cancer, colon cancer and glioblastoma cell lines (8, (12) (13) (14) (15) . In other tumor cells, altered hERG expression was associated with cell cycle regulation and proliferation (16, 17) . Recent work was reported showing a possible role for hERG inhibition in pediatric brain cancer, medulloblastoma (18) . The few studies that implicate hERG in GBM have used traditional cell lines or serum-cultured cells that lack the diverse genotypic and phenotypic characteristics observed in patient-derived tumors (19) . Furthermore, many prior studies were conducted in vitro and direct consequences of hERG expression on GBM tumors in situ or patient survival have not been reported. We set out to determine whether in vivo hERG expression of tumor xenografts initiated from glioblastoma patient-derived cells (GPDCs) (20) . We also sought to determine whether GPDC proliferation rates and GBM patient survival were affected by hERG channel inhibition.
We showed hERG expression levels are correlated with higher proliferation rates in GPDCderived xenografts and that patients with high hERG expressing GBM had worse survival rates.
We also demonstrate that hERG blockers reduced GPDC proliferation, and improved survival in patients who received one or more hERG blocking drugs but only if their tumors exhibited high hERG expression levels.
Materials and Methods

Isolation of GBM stem-like cancer cells (GPDCs)
GPDCs were isolated following protocols previously reported (19, (21) (22) (23) Sphere formation assay. GPDCs were enzymatically dissociated to single cells and seeded at 100 cells/well into 96-well plates. After cell recovery overnight, media was exchanged with drug-containing media at increasing concentrations o E-4031 . After two weeks GPDC spheres were counted, with drug-treated conditions normalized to vehicle controls. GPDC orthotopic xenograft model. GBM orthotopic xenografts were initiated as previously described (24) . GPDCs were enzymatically dissociated to single cells, and 2*10 5 cells were suspended in 5 µl of media. Using a Hamilton syringe, the cells were stereotactically implanted into the right striatum of anesthetized non-obese diabetic severe combined immunodeficient (Nod-SCID) mice between the ages of 8-10 weeks at 0.33 µl/min at the following coordinates referenced from bregma: 0 mm anteroposterior, +2.5 mm mediolateral, and -3.5 mm dorsoventral. At either 3 months or the onset of neurological symptoms, tumor formation was verified using magnetic resonance imaging (MRI). Mice were anesthetized, contrast enhanced using 10 mmol/kg of intraperitoneal gadodiamide (Omniscan; GE Healthcare, Piscataway, NJ), and placed onto a small animal MRI scanner (4.7-T horizontal bore imaging/spectroscopy system; Varian, Palo Alto, CA), and T1-and T2-weighted images were obtained. As per our approved animal protocol, once neurological symptoms were observed and the mice were moribund, which occurred between 80-120 days, implanted Nod-SCID mice were immediately euthanized by perfusion fixation with 4% paraformaldehyde.. Brains were then excised, embedded in paraffin, and processed for general histology.
Immunohistochemistry (IHC)
. IHC was performed on GBM mouse xenografts and a human TMA as previously described (22 were blindly scored as having high hERG expression or low hERG expression. In order to take into account the heterogeneity of GBM samples even from the same tumor, for patients that had multiple punches, if one punch had high hERG expression, the patient was denoted as having high expression levels. Survival analysis was done using a log-rank test and presented as a Kaplan-Meier survival plot with the addition of hazard ratio analysis. P-values <0.05 were considered statistically significant. Plots were generated using GraphPad Prism 6. 
Results
HERG expression levels in GBMs correlate with tumor proliferation rates
We evaluated whether hERG expression levels in vivo correlated with proliferation in a tumor xenograft assay, where four distinct GPDC lines were orthotopically implanted into the right striatum of non-obese diabetic severe combined immunodeficient (NOD-SCID) mice. H&E staining was used to visualize tumor xenografts in mouse brain (Fig. 1A1-D1 Ki-67-positive cells) (p=0.0005) (Fig. 1E) . Then, immunohistochemistry using a pan-hERG antibody on serial xenograft sections (Fig. 1A2-D2 and 114 GSC (33% of cells)], suggesting that hERG expression is associated with GBM proliferation (Fig.1F) . Interestingly, this data also shows that although hERG is overexpressed in GBMs with higher proliferation rates, not all GBM exhibit high hERG expression levels.
Research. 
Lower patient survival rates associated with hERG expression
To determine whether hERG expression correlated with patient survival, we examined a human tissue microarray (TMA) consisting of GBMs resected from the years 1999 to 2009 with 149 patients that had clinically accessible records for correlation. Of note, many of these patients were treated before the current standard temozolomide adjuvant chemoradiotherapy was established, and many current molecular markers (e.g. MGMT methylation, IDH mutation) were tested. Each patient had one to three 1-mm GBM specimen punches that were chosen by a neuropathologist to be the most representative areas of the entire patient GBM specimen.
Immunohistochemistry was performed on the TMA using the same pan-hERG antibody mentioned above, followed by blind scoring for low or high hERG expression levels. The blind scoring revealed that high hERG expression correlated with a worse survival rate compared with low hERG expression, based on the log-rank test (p=0.022) with a median survival of 43.5 weeks (N=45) compared to 60.9 weeks (N=70), respectively (Fig. 2) . Furthermore, patients with high hERG levels had a 61% greater chance of dying before patients with low hERG levels (logrank hazard ratio of 1.536). These findings indicate that hERG may be an informative survival biomarker for GBM patients.
Univariate and Multivariate Analysis of hERG expression
Univariate and multivariate analysis were used to determine whether the correlation of hERG expression with survival was influenced by any confounding variables. Patient gender, age, KPS score, temozolomide treatment, radiation treatment, and tobacco use were assessed as potential confounding variables. Univariate analysis was conducted to determine which factors influence patient survival rates. There was not a statistically significant difference in survival based on patient gender, age, or tobacco use; however, there was a statistically significant difference in survival based on KPS score (0.024), temozolomide treatment (<0.001), and radiation treatment (<0.001). Multivariate survival analysis using Cox's regression model was used to determine whether hERG expression is an independent biomarker for survival taking into account KPS score, temozolomide treatment, and radiation treatment. This analysis indicated that hERG expression level is an independent marker for GBM patient survival, with reduced survival rates for patients exhibiting high hERG expression levels compared to those with low hERG expression levels (p=0.003) ( Table 1) .
HERG blockers decreased sphere formation in high hERG expressing GBM cell lines
Based on hERG expression levels found in GSC-derived xenografts, we wanted to determine whether hERG blockers could decrease proliferation rates in high hERG expressing GPDC lines more than low expressing hERG GPDC lines. GPDCs were dissociated into single cells and 100 cells were seeded into a 96-well plate. E-4031, a known hERG-specific blocker, was added at increasing drug concentrations. (25) ,. After two weeks, spheres were counted and normalized to vehicle control. E-4031 decreased sphere formation at increasing drug concentrations, with a statistically significant difference in sphere formation seen at drug concentrations 5 uM. (Fig. 3) . This suggests that hERG blockers have the ability to decrease GPDC sphere formation and proliferation in a hERG-specific manner, and hERG inhibition might be a potentially useful GBM therapeutic strategy.
Patients who received hERG blockers had a better overall survival rate
To determine whether hERG blockers affected patient survival, we examined whether patients represented on the GBM tissue microarray received commonly-prescribed hERG blockers after their GBM diagnosis (26). Of the 110 patients analyzed, 66 patients received at least one of the following drugs known to exhibit off-target hERG block: phenytoin, haloperidol, Fig 1) . Patients prescribed at least one hERG blocker exhibited significantly enhanced survival compared to those who did not receive a hERG blocker, based on the log-rank test (p=0.0015) with a median survival of 69.6 weeks (N=66) and 43.5 weeks (N=44), respectively (Fig. 4) . Patients who did not receive a hERG blocker had a 64% greater chance of dying before patients who did receive a hERG blocker (log-rank hazard ratio of 1.790). This data suggest that hERG blockers may increase patient survival. Interestingly, of the 66 patients who received at least one hERG blocker, 7 patients received two or more hERG blockers and had a median survival of 73.9 weeks, also a statistically significant improvement in survival compared to those patients who did not receive a hERG blocker (p=0.0117). Patients who did not receive a hERG blocker were 71% more likely to die before patients who received two or more hERG blockers (log-rank hazard ratio of 2.344).
This suggests a patient survival benefit with greater hERG blockade.
hERG blockers enhance survival specifically for patients with high hERG expression levels Interestingly, the correlation of hERG blockers with survival was not statistically significant for patients on the tissue microarray with low hERG expressing GBM (p=0.4136) (Fig. 5A) . However, patients with high hERG expressing GBM who received a hERG blocker fared better than those who did not (p=0.0458) (Fig. 5B) , with a median survival of 56.5 weeks (N=15) compared to 34.8 weeks (N=16), respectively. Patients with high hERG expressing GBM who did not receive hERG blockers had a 66% greater chance of dying first (a log-rank hazard ratio of 1.906) compared to patients with high hERG expressing GBM who received a hERG blocker. This suggests that hERG blockers are beneficial for patients with high hERG expressing GBMs, and supports the idea that hERG blockers improve survival times via a direct action on 
hERG channels, rather than other targets for these drugs. Moreover, the findings suggest the potential of tailoring GBM treatments according to hERG expression level stratification.
Discussion
In this study, we found that upregulation of hERG expression correlated with greater tumor proliferation in heterogeneous GPDC-derived mouse xenografts and a worse patient survival rate. We found that the hERG blocker E-4031 decreased proliferation as assayed by sphere formation in a GPDC line exhibiting high levels of hERG expression, whereas blocking hERG in low hERG expressing lines does not decrease proliferation to the same extent. Survival was enhanced in patients receiving one or more hERG blockers, but only when their tumors exhibited high levels of hERG expression. These findings suggest that hERG may be a useful biomarker for GBM survival, and that non-torsadogenic hERG blockers may be potentially repurposed for adjuvant GBM therapy.
GBMs are heterogeneous and a variety of subtypes have been described (24, 27) .
Research to characterize differences in GBMs has led to a better understanding of GBM progression and new therapeutic targets (28, 29) . For example, the efficacy of temozolomide is affected by the methylation status of MGMT, an enzyme that repairs the DNA damage resulting from temozolomide's chemotherapeutic action (30) . Methylation of the MGMT promoter silences protein production, preventing repair of DNA damage and leads to tumor cell death (31) .
MGMT status is now commonly tested in patients and it is well documented that GBM with MGMT promoter methylation are associated with higher median survival (30) . Although since the current study was performed with a tissue microarray of GBM patients treated before the current standard of adjuvant temozomolide chemoradiation, and markers such as MGMT methylation and IDH mutation status were not known, we are working to confirm our findings with an updated GBM TMA. Other researchers have discussed the role of hERG as a novel biomarker for several other cancers and our work further supports this approach in GBM (32, 33) . If validated, hERG expression may be used in the future to stratify GBM patients for possibly hERG inhibitor adjuvant therapy.
Many drugs inhibit hERG channels off-target, but some of these lack the pro-arrhythmic risk associated with hERG block. Phenytoin, prescribed to control seizures for most patients in this study, poses little risk for torsades de pointes arrhythmia. However, other troubling side effects have led to substitution of other anti-epileptic drugs such as levetiracetam, which does not block hERG channels (34) . Whether this trend will affect survival of patients, especially those with tumors expressing high hERG levels, is unknown. Our study provides the rationale for clinical trials to determine whether other drugs targeting hERG may provide benefit as adjuvant therapies, by repurposing drugs such as fluoxetine (Prozac®), also a hERG blocker, to reduce tumor proliferation in a subset of patients with the added benefit of also treating depression.
While many FDA approved hERG blockers exist, some of them have the potential to cause arrhythmias due to cardiac hERG blockade especially under conditions of polypharmacy (35) . One way to avoid off-target effects of hERG blockade might be combination with tumor targeting agents, such as alkylphosphocholine (APC) analogs (36, 37) . Tumor cells are selectively targeted by long term APC retention, whereas normal tissues metabolize APCs. APC analogs can be modified by addition other moieties, such as radioactive iodine or optical fluorescence for diagnostic or therapeutic purposes (27, 28) . Based on our findings, hERG blockers that are already FDA approved for other purposes may be repurposed as new therapeutic options for GBM patients. Studies in other cancers, such as leukemia, have shown that specific hERG blockers can have therapeutic effects without causing cardiac toxicities (38) . Prospective clinical trials will be needed to test and validate hERG as a GBM biomarker, and potentially stratify GBM patients for hERG inhibitor adjuvant therapy. curve, based on hERG expression, was generated with a survival difference that was statistically significant (p= 0.022). Scale bar represents 250um. who received more than one hERG blocker were compared to patients that had not received any hERG blockers and there was a statistically significant difference in their survival (p=0.0015). were stratified based on whether or not they had high hERG or low hERG expression levels. In each group, patients were further stratified based on whether they had received a hERG blocker.
(A)There was not a statistically significant difference in survival between patients who had low hERG expression levels (p=0.4136); however, (B) there was a statistically significant difference 
